Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Brief Communication
  • Published:

Chronic myeloproliferative neoplasms

MicroRNA-101 expression is associated with JAK2V617F activity and regulates JAK2/STAT5 signaling

Leukemia volume 32, pages 1826–1830 (2018)Cite this article

Subjects

Philadelphia negative myeloproliferative neoplasms (MPNs) are clonal hematological diseases characterized by excessive production of mature blood cells. Exome sequencing of patient samples have showed a relatively low degree genomic complexity for these diseases [1]. The majority of MPN patients carry somatic mutations in the JAK2 gene, with the JAK2V617F missense mutation being the most common in polycythemia vera (PV, 95%) and essential thrombocythemia (ET, 60%) [2].

MicroRNAs (miRNAs) act as post-transcriptional regulators of gene expression, regulate signaling, and can diffuse from one cell to another through the extracellular space or the blood stream. However, although they have been implicated in the pathophysiology of multiple hematological malignancies, their role in MPNs and the effect of JAK2V617F mutation on miRNA expression has not been elucidated [3].

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1
Fig. 2

References

  1. Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013;369:2391–405.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  2. Nangalia J, Green AR. The evolving genomic landscape of myeloproliferative neoplasms. Hematology. 2014;2014:287–96.

    Article  PubMed  Google Scholar 

  3. Zhan H, Cardozo C, Raza A. MicroRNAs in myeloproliferative neoplasms. Br J Haematol. 2013;161:471–83.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  4. Cheng J, Guo S, Chen S, Mastriano SJ, Liu C, D’Alessio AC, et al. An extensive network of TET2-rargeting MicroRNAs regulates malignant hematopoiesis. Cell Rep. 2013;5:471–81.

    Article  PubMed  CAS  Google Scholar 

  5. Godfrey AL, Chen E, Pagano F, Ortmann CA, Silber Y, Bellosillo B, et al. JAK2V617F homozygosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant homozygous subclone. Blood. 2012;120:2704–7.

    Article  PubMed  CAS  Google Scholar 

  6. Hong S, Noh H, Chen H, Padia R, Pan ZK, Su S-B et al. Signaling by p38 MAPK stimulates nuclear localization of the microprocessor component p68 for processing of selected primary microRNAs. Sci Signal. 2013; 6. https://doi.org/10.1126/scisignal.2003706.

  7. Ha M, Kim VN. Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol. 2014;15:509–24.

    Article  PubMed  CAS  Google Scholar 

  8. Auyeung VC, Ulitsky I, McGeary SE, Bartel DP. Beyond secondary structure: Primary-sequence determinants license Pri-miRNA hairpins for processing. Cell. 2013;152:844–58.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  9. Hookham MB, Elliott J, Suessmuth Y, Staerk J, Ward AC, Percy MJ, et al. The myeloproliferative disorder-associated JAK2 V617F mutant escapes negative regulation by suppressor of cytokine signaling 3 The myeloproliferative disorder – associated JAK2 V617F mutant escapes negative regulation by suppressor of cytokine signaling 3. Blood. 2007;109:4924–9.

    Article  PubMed  CAS  Google Scholar 

  10. Gao S, Chen C, Wang L, Hong L, Wu J, Dong P, et al. Histone deacetylases inhibitor sodium butyrate inhibits JAK2/STAT signaling through upregulation of SOCS1 and SOCS3 mediated by HDAC8 inhibition in myeloproliferative neoplasms. Exp Hematol. 2013;41:261–70.

    Article  PubMed  CAS  Google Scholar 

  11. Quentmeier H, Geffers R, Jost E, Macleod RaF, Nagel S, Ro S, et al. SOCS2: inhibitor of JAK2V617F-mediated signal transduction. Leukemia. 2008;22:2169–75.

    Article  PubMed  CAS  Google Scholar 

  12. Vainchenker W, Delhommeau F, Constantinescu SN, Bernard OA. New mutations and pathogenesis of myeloproliferative neoplasms. Blood. 2011;118:1723–35.

    Article  PubMed  CAS  Google Scholar 

  13. Farhadi E, Zaker F, Safa M, Rezvani MR. miR-101 sensitizes K562 cell line to imatinib through Jak2 downregulation and inhibition of NF-κB target genes. Tumor Biol. 2016;37:14117–28.

    Article  CAS  Google Scholar 

  14. Bosson AD, Zamudio JR, Sharp PA. Endogenous miRNA and target concentrations determine susceptibility to potential ceRNA competition. Mol Cell. 2014;56:347–59.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

Download references

Acknowledgements

F.P. was supported by Fondazione Umberto Veronesi, and Institute Pasteur - Fondazione Cenci Bolognetti. We thank Dr. D.G. Kent, Dr. D. Prins, Dr. J. Park, and Dr. T. Klampfl for helpful discussion.

Author information

Authors and Affiliations

  1. Cambridge Institute for Medical Research and Wellcome Trust/MRC Stem Cell Institute, University of Cambridge, Hills Road, Cambridge, CB2 0XY, UK

    Francesca Pagano, Federico Comoglio, Jacob Grinfeld, Juan Li, Yvonne Silber & Anthony R Green

  2. Department of Haematology, University of Cambridge, Cambridge, CB2 0XY, UK

    Francesca Pagano, Federico Comoglio, Jacob Grinfeld, Juan Li, Yvonne Silber & Anthony R Green

  3. Department of Haematology, Cambridge University Hospitals NHS Foundation Trust Hills Road, Cambridge, CB2 0QQ, UK

    Jacob Grinfeld, Anna Godfrey & Anthony R Green

  4. Cambridge Blood and Stem Cell Biobank, Department of Haematology, University of Cambridge, National Health Service Blood and Transplant Cambridge Centre, Cambridge, UK

    Joanna Baxter

Authors
  1. Francesca Pagano
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Federico Comoglio
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jacob Grinfeld
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Juan Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Anna Godfrey
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Joanna Baxter
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yvonne Silber
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Anthony R Green
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anthony R Green.

Ethics declarations

Conflict of interest

The authors declare no conflict of interest.

Electronic supplementary material

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pagano, F., Comoglio, F., Grinfeld, J. et al. MicroRNA-101 expression is associated with JAK2V617F activity and regulates JAK2/STAT5 signaling. Leukemia 32, 1826–1830 (2018). https://doi.org/10.1038/s41375-018-0053-9

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41375-018-0053-9

Search

Advanced search

Quick links